How to Get Enclomiphene Citrate in Nevada

What Is Enclomiphene Citrate and Why Is It Prescribed in Nevada?

Enclomiphene citrate is the trans-isomer of clomiphene and acts as a selective estrogen-receptor modulator (SERM) at the hypothalamus and pituitary. By blocking estrogen negative feedback, it raises LH and FSH, which in turn stimulates the testes to produce more testosterone endogenously. Nevada physicians prescribe it off-label for men diagnosed with secondary hypogonadism who want to restore testosterone without suppressing their own hypothalamic-pituitary-gonadal (HPG) axis.

In Kim et al. (BJU Int, 2016, N=108), men receiving enclomiphene 12.5 mg or 25 mg daily achieved mean morning testosterone levels of 400 ng/dL and 500 ng/dL respectively after 3 months, compared with 166 ng/dL at baseline, while sperm concentration was maintained in both groups [1]. That contrasts sharply with exogenous testosterone therapy, which suppresses spermatogenesis in roughly 65% of men within 6 months according to the World Health Organization's male contraception trials [2]. For Nevada men who want to restore testosterone while preserving fertility, enclomiphene is often the first clinical choice.

Nevada's telehealth statute (NRS 630.020) permits licensed physicians, nurse practitioners, and physician assistants to evaluate patients and issue prescriptions via synchronous audio-video visits, making remote access to enclomiphene straightforward for residents across Clark, Washoe, and rural Nevada counties [3].

Nevada Legal Framework: Who Can Prescribe Enclomiphene Citrate?

Any Nevada-licensed prescriber with DEA registration and prescriptive authority may write for enclomiphene citrate. That includes MDs, DOs, nurse practitioners (APRNs) with a collaborative practice agreement or independent practice status, and physician assistants operating within their supervising physician's scope. Enclomiphene is not a controlled substance, so no Schedule II through V DEA form is needed [4].

The Nevada State Board of Pharmacy requires that compounded drugs dispensed to Nevada patients come from a pharmacy holding either a Nevada 503A compounding registration or a valid out-of-state 503A license with a Nevada non-resident pharmacy permit [5]. No FDA-approved commercial enclomiphene product is currently marketed in the United States. The FDA reviewed Androxal (enclomiphene citrate 12.5 mg and 25 mg) in New Drug Application 022133 but did not issue final approval; the drug therefore remains available only through compounding channels [6].

Because the prescribing event is off-label and the product is compounded, the prescriber must document medical necessity in the patient chart. Telehealth providers in Nevada typically satisfy this requirement with a completed intake form, lab results, and a clinical note confirming a secondary hypogonadism diagnosis (ICD-10 E29.1) [7].

Required Labs Before an Enclomiphene Citrate Prescription in Nevada

Labs are not optional. Every responsible Nevada prescriber, telehealth or in-person, will require bloodwork before issuing a first prescription.

The minimum panel accepted by most Nevada telehealth platforms mirrors the Endocrine Society's 2018 clinical practice guideline on male hypogonadism, which states: "We suggest measuring serum testosterone levels in men with consistent symptoms and signs, using a reliable assay" [8]. In practice, Nevada providers generally require:

• Total testosterone (morning draw, two separate measurements on different days per Endocrine Society guidelines) [8]
• LH and FSH (to distinguish secondary from primary hypogonadism)
• Estradiol (E2, sensitive assay)
• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (CMP)
• Prolactin (to rule out prolactinoma as a correctable cause)
• PSA for men over 40 [9]

Quest Diagnostics and LabCorp both operate draw sites throughout Nevada, including Las Vegas, Henderson, Reno, Sparks, and Carson City. Most telehealth platforms accept lab results drawn within the past 90 days. If your prior results are older than 90 days, a fresh draw is typically required.

A man with total testosterone consistently below 300 ng/dL on two morning draws, combined with LH and FSH values that are low or inappropriately normal (rather than elevated), meets the biochemical threshold for secondary hypogonadism [8]. Enclomiphene is not indicated for primary hypogonadism (high LH/FSH, low testosterone), because the testes themselves are the limiting factor in that situation and stimulating the pituitary further will not help [10].

How Telehealth Prescribing Works for Enclomiphene Citrate in Nevada

Nevada allows telehealth prescribing for non-controlled medications after a synchronous audio-video consultation. No prior in-person visit is required under state law as of 2024 [3].

The typical telehealth workflow for Nevada residents has four steps.

Step 1: Complete an online intake. You answer questions about symptoms (low energy, reduced libido, morning erection frequency, mood changes), medical history, and current medications. Most platforms take 10 to 15 minutes.

Step 2: Upload or order labs. If you already have qualifying labs (drawn within 90 days), you upload them. If not, the platform sends a requisition to a nearby Quest or LabCorp site. Results return in 24 to 72 hours for most panels.

Step 3: Synchronous video visit. A Nevada-licensed physician, APRN, or PA reviews your labs and symptoms. The visit typically lasts 15 to 20 minutes. The provider confirms secondary hypogonadism, documents off-label medical necessity, and discusses dosing options (usually starting at 12.5 mg/day with a possible uptitration to 25 mg/day at week 6 based on follow-up testosterone) [1].

Step 4: Prescription routing and dispensing. The provider sends the prescription electronically to a 503A compounding pharmacy licensed for Nevada. Shipping to a Nevada address typically takes 3 to 7 business days. Combined with the visit timeline, most patients report receiving their first supply within 5 to 10 business days of their initial appointment.

Follow-up labs are drawn at 6 to 8 weeks to confirm testosterone response and check hematocrit, which can rise with any testosterone-raising therapy [9].

Finding a 503A Compounding Pharmacy Licensed to Ship to Nevada

No single branded enclomiphene product is on retail pharmacy shelves in Nevada. You need a 503A compounding pharmacy. The FDA defines a 503A compounder as a state-licensed pharmacy that compounds drugs for individual patient prescriptions, as opposed to a 503B outsourcing facility that produces large batches without patient-specific orders [11].

To legally ship enclomiphene citrate to a Nevada address, a pharmacy must hold either:

1. An active Nevada pharmacy license issued by the Nevada State Board of Pharmacy, or
2. A valid non-resident pharmacy permit from the Nevada State Board of Pharmacy plus a home-state 503A compounding license [5].

You can verify a pharmacy's Nevada permit status at the Nevada State Board of Pharmacy license lookup portal. Always confirm before placing an order. The FDA has issued warning letters to 503A compounders producing drugs from bulk substances not on the approved 503A bulk drug list; enclomiphene citrate as a SERM is compounded under the prescriber's authority for an individually identified patient, but it is not on the current FDA 503A bulk drug substances list, meaning the pharmacy must use an FDA-approved active pharmaceutical ingredient (API) as the starting material [12].

Capsule and tablet forms are both available. Most compounders offer 12.5 mg and 25 mg capsules. Tablets generally have a slightly lower cost per unit but the clinical difference in absorption is minimal based on available pharmacokinetic data [1].

Insurance Coverage and Cost of Enclomiphene Citrate in Nevada

Nevada Medicaid does not cover enclomiphene citrate for secondary hypogonadism because the indication is off-label and the product is compounded rather than an FDA-approved drug [13]. Most commercial insurers follow the same logic. Prior authorization is unlikely to succeed for this specific agent, but some plans will approve clomiphene citrate (the racemic mixture) because it carries older FDA approval for ovulation induction and has an established prescribing history in men [14].

Out-of-pocket costs through telehealth platforms vary. A monthly supply of compounded enclomiphene citrate (12.5 mg to 25 mg/day, 30 capsules) typically runs $60 to $120 depending on the pharmacy and dose. Telehealth consultation fees range from $99 to $199 for the initial visit, with follow-up visits at $49 to $99. Some platforms bundle the pharmacy cost and provider fee into a monthly membership of $150 to $250 that includes labs, visits, and medication.

If cost is a barrier, clomiphene citrate 25 mg every other day is an accessible alternative that several Nevada prescribers use off-label. A 30-tablet supply of generic clomiphene costs under $30 at most retail pharmacies and produces broadly similar LH/FSH stimulation, though enclomiphene's single-isomer profile means less anti-estrogenic activity at the retina and potentially fewer visual side effects [15].

Transferring an Existing Enclomiphene Prescription to Nevada

If you move to Nevada or switch providers, your existing enclomiphene prescription can be transferred to a new Nevada-licensed pharmacy or re-issued by a new Nevada provider. Because enclomiphene is not a controlled substance, there are no federal restrictions on transferring a compounded prescription between pharmacies [4]. The receiving pharmacy will need the original prescription or a new prescription from a Nevada-licensed provider, along with your dispensing history.

If your previous provider was in another state, that provider cannot continue prescribing to a Nevada address unless they hold a Nevada medical license or qualify under interstate telehealth reciprocity. Nevada participates in the Interstate Medical Licensure Compact (IMLC), which streamlines licensing for physicians already licensed in another IMLC member state [16]. Practical timelines for IMLC licensure range from 30 to 90 days, so most patients simply establish care with a new Nevada provider rather than waiting for their out-of-state physician to obtain a Nevada license.

Monitoring and Follow-Up After Starting Enclomiphene Citrate in Nevada

Starting enclomiphene is not a one-time prescription event. Ongoing monitoring confirms efficacy and catches the small number of men who develop clinically significant estradiol elevation.

The Endocrine Society's 2018 guideline recommends re-measuring testosterone 3 months after initiating treatment, then annually if levels are stable [8]. Most Nevada telehealth platforms schedule a mandatory 6 to 8 week lab recheck. At that visit, the provider reviews:

• Total and free testosterone (target: 400 to 700 ng/dL for most symptomatic men)
• Estradiol (target: below 40 pg/mL on sensitive assay; values above 60 pg/mL may warrant dose reduction or an aromatase inhibitor) [9]
• Hematocrit (target: below 54% per FDA testosterone product labeling safety data) [17]
• LH and FSH (to confirm the HPG axis is responding)

In the Kim et al. trial, 12.5 mg daily produced a mean testosterone of 400 ng/dL and 25 mg daily produced 500 ng/dL at 3 months, with no serious adverse events reported in either group [1]. The most common side effects were mild mood changes and visual blurring, both dose-dependent and reversible on discontinuation.

Men wishing to assess fertility impact should add a semen analysis at 3 months. Unlike exogenous testosterone, enclomiphene maintained sperm concentration and motility in that same trial, with mean sperm concentration of 33 million/mL in the 12.5 mg group versus 29 million/mL at baseline [1]. The American Urological Association's 2018 male infertility guideline notes that clomiphene-class agents are among the recommended options for men with secondary hypogonadism and concurrent subfertility [18].

What Prior Authorization Documentation Nevada Insurers Require

The small subset of Nevada commercial plans that will consider enclomiphene or clomiphene for secondary hypogonadism typically require:

• Two morning total testosterone values below 300 ng/dL, drawn on separate days
• LH and FSH results confirming secondary (not primary) etiology
• A chart note with ICD-10 code E29.1 (testicular hypofunction) [7]
• Documentation that a generic FDA-approved testosterone product was considered but is contraindicated or declined due to fertility concerns
• Prescriber attestation that the compounded product is medically necessary because no commercially available alternative meets the patient's clinical needs

Prior authorization approval rates for compounded enclomiphene remain low (industry estimates under 15% for off-label compounded agents). Patients should budget for out-of-pocket costs as the default scenario.

The Centers for Medicare and Medicaid Services defines compounded drugs as generally excluded from Part D coverage, which affects Medicare-eligible Nevada men over 65 who might otherwise expect pharmacy benefit coverage [13].

Nevada-Specific Practical Notes

Clark County (Las Vegas metro) and Washoe County (Reno metro) both have in-person men's health and urology clinics that prescribe enclomiphene, including academic practices affiliated with UNLV School of Medicine and University of Nevada Reno School of Medicine. Rural Nevada residents in Elko, Fallon, or Winnemucca are best served by telehealth given the distances involved.

Nevada does not require a prior in-person physical examination before a telehealth prescriber may issue a prescription for a non-controlled substance, as confirmed in the Nevada Division of Public and Behavioral Health telehealth guidance updated in 2023 [3]. That makes telehealth the fastest access route for most Nevada men.

Same-day access is possible if you use a local 503A compounder in Las Vegas or Reno and present to an in-person clinic with qualifying labs already in hand. Most men following that path receive their medication the same afternoon. Without existing labs, the fastest realistic timeline from first contact to first dose is 48 to 96 hours via telehealth plus expedited lab processing.